Eli Lilly continues near-monthly M&A presence with $2.9bn Merida deal - Pharmaceutical Technology

Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED). Merida's lead programme, MER511, is in Phase I development for Graves' disease and thyroid eye disease (TED). Merida is designing drugs that are engineered to selectively degrade pathogenic autoantibodies, proteins behind various autoimmune diseases. Credit: Anusorn Nakdee/Shutterstock.com. Eli Lilly has once again returned to the M&A table, striking a $2.875bn agreement to buy autoimmune and allergic disease drug developer Merida Biosciences. The deal for Merida, which includes upfront and milestone payments, sees Lilly bolster its pipeline with biologics engineered to selectively degrade pathogenic…

Source: Pharmaceutical Technology